Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups

Share :
Published: 13 Dec 2021
Views: 266
Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr Abhishek Maiti speaks to ecancer in an online interview for the virtual ASH 2021 meeting about updated outcomes in genomic subgroups from a phase II trial of ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukaemia (AML).

He explains the background of this update, which found DEC10-VEN to offer better outcomes compared to intensive chemotherapy in older patients with newly diagnosed or relapsed/refractory AML.

Dr Maiti reports outcomes across various genomic subgroups, some of which were favourable while others were suboptimal.